JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Becton Dickinson and Co

Затворен

СекторЗдравеопазване

185.78 1.25

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

185.31

Максимум

185.87

Ключови измерители

By Trading Economics

Приходи

27M

330M

Продажби

104M

5.3B

P/E

Средно за сектора

33.913

38.156

EPS

3.35

Дивидентна доходност

2.23

Марж на печалбата

6.259

Служители

70,000

EBITDA

93M

546M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+8.32% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

2.23%

2.50%

Следващи печалби

7.08.2025 г.

Следваща дата на дивидент

30.09.2025 г.

Следваща дата на екс-дивидент

8.09.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-15B

50B

Предишно отваряне

184.53

Предишно затваряне

185.78

Настроения в новините

By Acuity

16%

84%

20 / 375 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Becton Dickinson and Co Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

14.07.2025 г., 14:26 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14.07.2025 г., 11:08 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

14.07.2025 г., 10:37 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

1.05.2025 г., 11:18 ч. UTC

Печалби

Becton 2Q Net Down, Warns of Tariff Hit on 2025 EPS

15.07.2025 г., 18:32 ч. UTC

Придобивния, сливания и поглъщания

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15.07.2025 г., 18:31 ч. UTC

Придобивния, сливания и поглъщания

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14.07.2025 г., 16:12 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14.07.2025 г., 15:06 ч. UTC

Придобивния, сливания и поглъщания

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14.07.2025 г., 14:11 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14.07.2025 г., 10:53 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14.07.2025 г., 10:22 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14.07.2025 г., 10:22 ч. UTC

Придобивния, сливания и поглъщания

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14.07.2025 г., 10:22 ч. UTC

Придобивния, сливания и поглъщания

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14.07.2025 г., 10:21 ч. UTC

Придобивния, сливания и поглъщания

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14.07.2025 г., 10:20 ч. UTC

Придобивния, сливания и поглъщания

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14.07.2025 г., 10:19 ч. UTC

Придобивния, сливания и поглъщания

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14.07.2025 г., 10:19 ч. UTC

Придобивния, сливания и поглъщания

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14.07.2025 г., 10:18 ч. UTC

Придобивния, сливания и поглъщания

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14.07.2025 г., 10:18 ч. UTC

Придобивния, сливания и поглъщания

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14.07.2025 г., 10:17 ч. UTC

Придобивния, сливания и поглъщания

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14.07.2025 г., 10:16 ч. UTC

Придобивния, сливания и поглъщания

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14.07.2025 г., 10:16 ч. UTC

Придобивния, сливания и поглъщания

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

14.07.2025 г., 10:15 ч. UTC

Придобивния, сливания и поглъщания

Waters to Combine With Becton Dickinson's Biosciences & Diagnostic Solutions Business >WAT BDX

14.07.2025 г., 10:15 ч. UTC

Придобивния, сливания и поглъщания

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine

1.05.2025 г., 10:33 ч. UTC

Печалби

Becton Dickinson Cuts FY25 Adj EPS View on Tariff Impact

1.05.2025 г., 10:33 ч. UTC

Печалби

Becton Dickinson FY25 Adj EPS View Includes an Estimated Tariff Impact of Approximately 25c

1.05.2025 г., 10:32 ч. UTC

Печалби

Becton Dickinson Sees FY25 Organic Rev Growth Guidance of 3.0% to 3.5% >BDX

1.05.2025 г., 10:32 ч. UTC

Печалби

Becton Dickinson Narrows FY25 View To Rev $21.8B-$21.9B >BDX

1.05.2025 г., 10:31 ч. UTC

Печалби

Becton Dickinson Intends To Invest $2.5 B in U.S. Manufacturing Capacity Over the Next 5 Years >BDX

1.05.2025 г., 10:31 ч. UTC

Печалби

Becton Dickinson: Taking 'Decisive Mitigation Actions to Navigate the Current Macro Environment' >BDX

Сравнение с други в отрасъла

Ценова промяна

Becton Dickinson and Co Прогноза

Ценова цел

By TipRanks

8.32% нагоре

12-месечна прогноза

Среден 200.73 USD  8.32%

Висок 255 USD

Нисък 172 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Becton Dickinson and Co през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

13 ratings

4

Купи

9

Задържане

0

Продай

Техническа оценка

By Trading Central

167 / 206.99Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

20 / 375 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.